RE: Valuation disconnects5 Jan 2023 14:07
OAMOT.
And then big Al can concentrate on his baby affimers.
Platform Technologies
* Affimer® molecules are engineered alternatives to antibodies that have significant competitive advantages including size, stability, versatility, rapid development and ease of production. Despite their shortcomings, antibodies currently dominate markets, such as diagnostics and therapeutics, worth in excess of $100 billion!!
Al and Avacta have not even begun.